Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell Transplantation

Title: Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell Transplantation

Volume: 8 Issue: 3

Author(s): U. Hainz, B. Jurgens, T. Wekerle, M. G. Seidel and Andreas Heitger

Affiliation:

Keywords: Indoleamine 2,3-dioxygenase, HSCT, T-cell, transplantation, tolerance, inflammation, CTLA4, GVHD

Abstract: Hematopoietic stem cell transplantation (HSCT) is complicated by unwelcome side-effects that arise on the basis of an altered immune system. Infectious complications and alloreactive T-cell responses trigger a process of ongoing immune activation and inflammation. Negative-feedback mechanisms to counteract inflammation involve the induction of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO), which mediates anti-inflammatory activities and T-cell inhibition via tryptophan catabolism. However, persistent immune activation and generalized release of pro-inflammatory cytokines deviate immune regulation towards chronic suppression incapable to abrogate the inflammatory response. This review focuses on the unique role of tryptophan catabolism in modulating inflammatory processes and T-cell responses after HSCT.

Cite this article as:

Hainz U., Jurgens B., Wekerle T., Seidel G. M. and Heitger Andreas, Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell Transplantation, Current Drug Metabolism 2007; 8 (3) . https://dx.doi.org/10.2174/138920007780362554